CVR - Coronavirus Vaccines R&D Roadmap

Milestone
3.1.b

Use cases

In progress

Develop initial use cases for broadly protective coronavirus vaccines, defining how, where, and under what circumstances such vaccines would be used, such as defining target populations, addressing cold-chain and vaccine stability considerations, and exploring equitable access in resource-constrained settings. Following initial development, the use cases and PPCs may need to be modified over time through an iterative process.

Progress Highlights

Whittaker 2025 used mathematical modelling to demonstrate the utility of different implementation strategies of broadly protective sarbecovirus vaccines in the early stages of a hypothetical SARS-X outbreak.

CEPI and CIDRAP hosted a workshop on April 18, 2024 to: 1) identify how investigational or licensed broadly protective coronavirus vaccines (BPCV) would be used in the future, 2) identify the most desirable implementation strategies and use cases for the BPCV, 3) inform the current projects in CEPI’s portfolio to ensure that the work done can support the future use of the vaccines, and 4) guide future CEPI investments and program strategy.